Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Three patient deaths have forced Novartis and Bristol Myers Squibb to suspend multiple CAR T-cell trials targeting autoimmune diseases. The culprit: a rare but deadly immune reaction called IEC-HS. Researchers are now scrambling to understand what went wrong — and how to move forward safely.
CAR T-cell therapy was riding high as a potential game-changer for autoimmune diseases like lupus, scleroderma, and multiple sclerosis — until three patient deaths brought the momentum to a halt. Novartis suspended eight clinical trials of its autoimmune CAR T product, rap-cel, after all three fatalities were linked to immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS), a rare but severe hyperinflammatory reaction. Bristol Myers Squibb followed with a voluntary pause on its rival product, zola-cel, out of caution.
IEC-HS is distinct from the more commonly discussed cytokine release syndrome (CRS) — it typically emerges after CRS has peaked and involves a runaway feedback loop between CAR T cells and host macrophages. Experts believe rapid manufacturing methods used by both companies may have contributed by producing highly potent cells that trigger excessive immune activation once infused into already-inflamed autoimmune patients.
Key Takeaways:
Why it matters: CAR T-cell therapy holds transformative promise for autoimmune diseases, but these deaths underscore that translating oncology tools into rheumatology requires a deeper understanding of immune biology — and a highly skilled, vigilant clinical team.
